Trial Profile

A multicentre, open-label, randomised, controlled non-inferiority study comparing the effect of discontinuing versus continuing methotrexate (MTX) alongside certolizumab pegol (CZP) in rheumatoid arthritis (RA)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2025 New trial record
05 Apr 2025 Primary endpoint (the proportion of patients maintaining LDA without a flare (i.e., a CDAI score > 10 or intervention with rescue treatments for any reason) at week 36 (24 weeks after MTX discontinuation)), has been met, according to the results presented in the Arthritis Research and Therapy.
05 Apr 2025 Results presented in the Arthritis Research and Therapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com